BridgeBio Pharma and Sentynl Therapeutics receive marketing authorisation in the EU for Nulibry (fosdenopterin) for the treatment of MOCD type A

BridgeBio Pharma

20 September 2022 - Nulibry was BridgeBio’s first FDA approved therapeutic; Sentynl acquired global rights to Nulibry in March 2022.

BridgeBio Pharma and Sentynl Therapeutics today announced the European Commission has granted marketing authorisation for Nulibry (fosdenopterin) as the first therapy for the treatment of patients with molybdenum cofactor deficiency Type A.

Read BridgeBio Pharma press release 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe